NPPA computed the Retail Price of Linagliptin 5 mg + Empagliflozin 25 mg + Metformin Hydrochloride (As Extended Release) IP 1000 mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Unison Pharmaceuticals Pvt. Ltd. (Marketer)

Mar 16, 2026 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific Compliance

The National Pharmaceutical Pricing Authority (NPPA) on March 06, 2026, issued the Computation of Retail Price of Linagliptin 5 mg + Empagliflozin 25 mg + Metformin Hydrochloride (As Extended Release) IP 1000 mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Unison Pharmaceuticals Pvt. Ltd. (Marketer).

The following has been stated namely: -

• The Retail Price has been computed based on the data from August 2025

• The Retail Price has been computed for Each Film Coated Tablet Containing Linagliptin 5 mg + Empagliflozin 25 mg + Metformin Hydrochloride (As Extended Release) IP 1000 mg for M/s Exemed Pharmaceuticals (Manufacturer) & M/s Unison Pharmaceuticals Pvt. Ltd. (Marketer)

• The Total MAT is 2,02,67,746

[Notification No. 19(5058)/2026/DP/NPPA/Div.II]


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT